Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Pregene Out-licenses CAR-T to CellPoint for $22 Million in Near-Term Payments

publication date: Apr 6, 2022

Shenzhen Pregene Biopharma out-licensed US-EU rights for its anti-BCMA CAR-T candidate to CellPoint, a Dutch cell therapy company. CellPoint will make $22 million in upfront and near-term milestones, plus other unspecified milestones and royalties. CellPoint is developing CAR-T therapeutics for point-of-care use based on a Lonza device, Cocoon, which facilitates automated manufacturing of the CAR-T in one week. CellPoint has also started two clinical trials of its own CAR-T candidate that targets CD19 CAR for NHL and CLL. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here